Browse by author
Lookup NU author(s): Professor Linda Sharp
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).
Background: Prior evidence suggests a role for statins in the management of cancer. However, the benefit of statin use in the adjuvant setting remains uncertain. This study investigates associations between statin use initiated after a breast cancer diagnosis and mortality.Methods: Women with stage I-III breast cancer were identified from the National Cancer Registry of Ireland (N = 4243). Post-diagnostic statin initiators were identified from pharmacy claims data (N = 837). Multivariate models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between de novo statin use and mortality.Results: The median duration of statin use was 6.7 years. No association was found between post-diagnostic statin use and breast cancer-specific (HR 0.88, 95% CI 0.66, 1.17) or all-cause mortality (HR 1.00, 95% CI 0.82, 1.21).Conclusions: The results from our study suggest that initiating statin use after a diagnosis of stage I-III breast cancer is not associated with a reduction in breast cancer-specific mortality.
Author(s): Smith A, Murphy L, Sharp L, O'Connor D, Gallagher WM, Bennett K, Barron TI
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 2016
Volume: 115
Issue: 5
Pages: 592-598
Print publication date: 23/08/2016
Online publication date: 02/08/2016
Acceptance date: 06/07/2016
Date deposited: 11/06/2017
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/bjc.2016.232
DOI: 10.1038/bjc.2016.232
Altmetrics provided by Altmetric
